HLHNEHRNCT07800234
Establishing a National Egyptian HLH Registry (NEHR)
An observational study of HLH and Hemophagocytic Lymphohistiocytoses, run by Ain Shams University at 2 sites in Egypt.
Trial summary
Establishing a National Egyptian HLH Registry (NEHR) Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- HLH, Hemophagocytic Lymphohistiocytoses
- How many people
- 100 participants
- Where
- 2 sitesEgypt
- Study dates
- 2 Mar 2024to 1 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients diagnosed with hlh
Who may be able to join
- patients diagnosed with hlh
Who cannot join
- adults
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Iman Ragab Prof of Pediatrics, Ain Shams University, Professor contact
Fatma Ebeid Professor of pediatrics, Ain Shams University, Professor contact
Egypt2 sites, 1 recruiting
- Recruiting
Faculty of Medicine Pediatric Hematology Oncology Department
Cairo, 11566
Iman Ragab Professor of Pediatrics, MD, +201095569596, hragab68@hotmail.com
Fatma Soliman Elsayed Ebeid Professor of Pediatrics, MD, +201095569596, fatmaebeid@med.asu.edu.eg
- Active, not recruiting
Faculty of medicine ain shams university
Cairo
About this study
Establishing a National Egyptian HLH Registry (NEHR)
- Conditions
- HLH, Hemophagocytic Lymphohistiocytoses
- Medical subject headings
- Lymphohistiocytosis, Hemophagocytic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hemophagocytic lymphohistiocytosis (HLH) | Children diagnosed with Hemophagocytic lymphohistiocytosis (HLH) |
What is being measured
The primary outcome is the main question the study is designed to answer.
A nationwide HLH map
Establish a nationwide map for children with presumed diagnosis of HLH
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start2 Mar 2024
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HLHStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Iman Ragab, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07800234
- Sponsor's protocol ID
- FMASU P05/2024
- Acronym
- NEHR
- Status last verified
- Aug 2026
- First submitted
- 30 Aug 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing a National Egyptian HLH Registry (NEHR)
- ClinicalTrials.gov ID
- NCT07800234
- Acronym / sponsor ID
- NEHR / FMASU P05/2024
- Conditions
- HLH, Hemophagocytic Lymphohistiocytoses
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 2 Mar 2024 (actual)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 2 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Establishing a National Egyptian HLH Registry (NEHR)
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hemophagocytic lymphohistiocytosis (HLH) | – | –Children diagnosed with Hemophagocytic lymphohistiocytosis (HLH) |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients diagnosed with hlh
Key inclusion criteria (1 listed)
- patients diagnosed with hlh
Key exclusion criteria (1 listed)
- adults
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
A nationwide HLH map
Time frame: 2 years
Establish a nationwide map for children with presumed diagnosis of HLH
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for HLH
Not yet recruitingObservational study
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
RecruitingObservational study
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Hemophagocytic Lymphohistiocytosis (HLH)
Not yet recruitingPhase 3
Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)
Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis
Not yet recruitingPhase 2
Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
Bone Marrow Failure, Hemoglobinopathies
Not yet recruitingPhase 2/3
All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Iman Ragab Prof of Pediatrics, Ain Shams University, Professor contact
Fatma Ebeid Professor of pediatrics, Ain Shams University, Professor contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HLH and Hemophagocytic Lymphohistiocytoses, run by Ain Shams University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Iman Ragab Prof of Pediatrics, Ain Shams University, Professor (+20 1002550680, hragab68@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
A nationwide HLH map (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.